Empowering Compliance and Channel Risk Management in Pharma: Leveraging Data Amid Regulatory Challenges | VBPulse Select Webinar
Amid the deepening of the centralized rectification campaign in the pharmaceutical sector, systemic risk points within the industry have not only been exposed, but a more stringent regulatory environment for compliance management is also on the horizon, presenting unprecedented challenges. Consequently, the construction of compliance systems and channel risk control have once again been placed at the core of pharmaceutical enterprises’ operations and industry development.
For pharmaceutical companies, heightened compliance requirements translate into higher operational costs and more stringent market access standards.Pharmaceutical companies face numerous challenges in the practical implementation of compliance management. On one hand, enterprises must comprehensively review their compliance management status, requiring refined adjustments and improvements across multiple key elements, including organizational structure, risk assessment, business processes, and monitoring and training. On the other hand, there is a need for methodological updates in areas such as the control of sales and promotional expenses, the identification and response to compliance risks, and innovation in data management models.
As globalization continues to advance and international collaboration becomes a major trend in the pharmaceutical industry, the exploration of potential partnerships based on global data resources, along with partner due diligence and risk assessment, is gradually becoming an essential requirement.For example, to ensure the most comprehensive screening of risk events involving partners and their affiliates, it is necessary to efficiently extract key insights from vast amounts of information and continuously monitor partners’ business operations.
Therefore, digital transformation has become a critical, innovative, and intrinsic solution.How to empower decision-making processes such as compliance system development, cost control, and risk management through digitalization, how to establish effective compliance mechanisms, and how to gain a deep understanding of the current compliance landscape are challenges currently faced by pharmaceutical companies.
This session of “VBInsight Select Open Course” features Scott Xiao (Xiao Shuheng), Key Account Management Manager at Dun & Bradstreet, and Farley Lyu (Lü Chengjie), Senior Consultant in the Products and Solutions Department at Dun & Bradstreet, who will present"Empowering Pharmaceutical Enterprises' Channel Risk Management with Data: Insights from Case Studies," "The Hidden Iceberg of Risks Beneath the Surface of Channel Data Management"Topic Sharing: An In-Depth Exploration of Core Elements in Compliance and Risk Management within the Pharmaceutical Industry, Discussing Opportunities and Practical Applications Brought by Digital Empowerment to Pharmaceutical Enterprises.
As one of the most influential global providers of business information services, Dun & Bradstreet, founded in 1841, maintains the world’s largest database of enterprise information and has become one of the oldest credit reporting agencies globally. Dun & Bradstreet has established the world’s most widely recognized “business identity identification system,” known as the D-U-N-S Number®.Over 90% of the Fortune Global 500 companies are Dun & Bradstreet’s clients. With 180 years of development, Dun & Bradstreet leverages its global data advantages and analytical capabilities to help businesses increase revenue, reduce costs, manage risks, and achieve global expansion.
Scan the QR code now to reserve your spot for the live broadcast, and receive two complimentary resource linkage services.
Scott Xiao (Xiao Shuheng)
Manager, Key Account Management Department, Dun & Bradstreet, with over seven years of experience in risk advisory services within the pharmaceutical industry, providing full-lifecycle channel management consulting services to various segments including pharmaceuticals, medical devices, OTC products, nutritional supplements, and veterinary medicines.Analyze the policy background and current channel landscape, leveraging Dun & Bradstreet’s advanced technologies and robust data capabilities to help clients gain insights into channel risks. We are committed to enhancing channel health and empowering decision-making with authentic and accurate channel data.. The scope of services includes: conducting authenticity and compliance verification and assessment of channel partners during the onboarding process, as well as data monitoring and risk identification across the upstream and downstream channel ecosystem.
Farley Lyu (Chengjie Lv)
Senior Consultant, Dun & Bradstreet Products and Solutions Division, with over seven years of experience in risk consulting services for the pharmaceutical industry, specializing in providing specialized and customized full-lifecycle services to enterprises in the life sciences and healthcare sectors.Leveraging Dun & Bradstreet’s advanced data analytics and insights, combined with industry context and professional judgment, we help clients proactively manage compliance risks, enhance compliance performance, and optimize operational efficiency within complex regulatory environments, ensuring that enterprises maintain their leadership and competitive advantage in a dynamic market landscape.Service Scope: Conduct authenticity and compliance verification and assessment of third parties, continuously monitor sales and procurement activities, and promptly identify and track anomalies.
“VBSelect Open Courses” is one of the branded columns under VCBeat’s “VBSelect” series. Focusing on pain points in the medical industry and systematic solutions, it leverages an online live-streaming platform for knowledge sharing and exchange. By continuously inviting seasoned industry practitioners and experts to co-develop a series of thematic courses, it aims to provide healthcare enterprises with in-depth, high-value content. VBSelect Open Courses: Making the selection of knowledge simpler.